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Synopsis
Objectives: Candida albicans is the most prevalent fungal pathogen of humans, causing a 
wide range of infections from harmless superficial to severe systemic infections.  
Improvement of the antifungal arsenal is needed since existing antifungals can be associated 
with limited efficacy, toxicity and antifungal resistance. In this respect, we aimed to identify  
compounds to identify compounds acting synergistically with echinocandin antifungals and  
that could contribute to a faster reduction of the fungal burden.
Methods: 38,758 compounds were tested for their ability to act synergistically with  
aminocandin, a β--glucan synthase inhibitor of the echinocandin family of 
antifungals. The synergy between echinocandins and an identified hit was studied with 
chemogenomic screens and test of individual Saccharomyces cerevisiae and C. albicans  
mutant strains.
Results: We found that colistin, an antibiotic that targets membranes in Gram negative 
bacteria, is synergistic with drugs of the echinocandin family on all Candida species tested. 
The combination of colistin and aminocandin led to faster and increased permeabilization of 
C. albicans cells than either colistin or aminocandin alone. Echinocandin sensitivity was a 
pre-requisite to be able to observe the synergy. A large-scale screen for genes involved in 
natural resistance of yeast cells to low doses of the drugs, alone or in combination, identified  
efficient sphingolipid and chitin biosynthesis as necessary to protect S. cerevisiae and C. 
albicans cells against the antifungal combination.
Conclusions: These results suggest that echinocandin-mediated weakening of the cell wall 
facilitates colistin targeting of fungal membranes that in turn reinforces the antifungal activity 
of echinocandins.
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Introduction
Invasive fungal infections (IFI) have emerged as a major cause of infectious complications in  
hospitalized patients with serious underlying diseases, especially those undergoing treatment  
of haematological malignancies or hospitalized in ICUs.1,2 Recent and comprehensive 
epidemiological surveys have reported that invasive candidiasis accounts for approximately  
75% of all IFI3,4, and Candida species are now recurrently found among the five leading 
causes of nosocomial bloodstream infections.5,6 Invasive candidiasis remains associated with a 
significant mortality, in the range of 40%5,7, even in patients receiving antifungals of the 
echinocandin class. However, recent studies suggest that early antifungal treatment and the  
use of echinocandins might be optimal for patient survival and therapeutic success 1,8-10. In this 
respect, it can be postulated that compounds that enhance the efficacy of echinocandins c ould 
contribute to a faster reduction of the fungal burden and have the potential to provide a  
breakthrough in the management of invasive candidiasis.
The main objective of the present study was to identify compounds acting synergistically with 
echinocandins, ie compounds that when combined with echinocandins would have a greater 
antifungal effect than the sum of the effects of the two individual compounds.11 We have 
screened a collection of 38,758 compounds in order to identify those that would increase the  
antifungal activity of aminocandin (IP960; HMR3270; NXL201)12, a non-marketed 
echinocandin to which we had easy access. We found that the antibiotic colistin showed 
synergism with aminocandin and another echinocandin, caspofungin13 in all Candida species 
tested. Colistin (polymyxin E) is a member of the polymyxin family of antibiotics that show 
efficacy towards Gram-negative bacteria.14 Polymyxins are cationic cyclic heptapeptides with  
a hydrophobic tail that interacts with the bacterial cytoplasmic membrane, therefore changing  
its permeability and triggering cell death.14 Notably, weak antifungal activity of colistin and 
polymyxin B has been previously reported.15,16 Moreover, polymyxin B was shown to 
synergize with polyenes and azole antifungals and it has been proposed that azole-induced  
changes in the ergosterol content of fungal membranes might enhance the pore-forming 
activity of polymyxins.17-19 In contrast to azoles and polyenes that impact fungal membranes,  
echinocandins are lipopeptides that target cell wall biosynthesis through non-competitive  
inhibition of β-1,3-glucan synthase, the product of the FKS1 gene in C. albicans.20 Moreover, 
echinocandins are proposed to act at the outer face of the plasma membrane 21 making it 
unlikely that their synergy with colistin has the same basis as that observed with azoles. 
Hence, we have further investigated the synergy between echinocandins and colistin with  
chemogenomic screens and test of individual mutant strains. Our data suggest that  
echinocandin-mediated alteration of the cell wall might facilitate colistin access to and  
perturbation of fungal membranes that in turn facilitate echinocandin activity.
Materials and methods
Strains and media
Clinical or reference isolates of C. albicans (SC531422), clinical isolates of Candida 
lusitaniae (NEM_7104301), Candida parapsilosis (NEM_7103546), Candida glabrata 
(NEM_7118432), Candida tropicalis (NEM_7114236), Candida krusei (ATCC6258; LGC 
Standards, Molsheim, France), Yarrowia lipolytica (NEM_7115511) and laboratory isolates of 
S. cerevisiae (BY4741, BY474323) were used in this study. Fluconazole- and caspofungin-
resistant strains used in this study are listed in Table 1 and were obtained from D. Perlin  
(PHRI, New Jersey, USA) and D. Sanglard (CHUV, Lausanne, Switzerland). Strains were 
routinely grown at 30 °C in Yeast Peptone Dextrose medium (YPD; 1% yeast extract, 2% 
peptone, 2% glucose), or Synthetic Dextrose minimal medium (SD; 0.67% yeast nitrogen 
base without amino acids (Difco), 2% glucose) and 2% agar for solid media. RPMI 1640 
glutamax medium (Invitrogen) buffered with 50 mM Hepes (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), pH 7 was used for screening compounds that synergize with  
aminocandin and for chequerboard assays. Alternatively RPMI 1640 glutamax medium 
buffered with 0.165 M MOPS (3-(N-morpholino)propanesulfonic acid) was used. 
Aminocandin (a kind gift from Dr. Dominique Lebeller), caspofungin (MSD), colistin sulfate 
(Sigma-Aldrich, Saint-Quentin Fallavier, France), colistin sodium methanesulfonate (Sigma-
Aldrich), hygromycin B (Sigma-Aldrich), nourseothricin (Werner BioAgents, Jena, Germany) 
and 5-fluorocytosine (Sigma-Aldrich) were dissolved in H2O. Fluconazole (Sigma-Aldrich) 
and amphotericin B (Sigma-Aldrich) were dissolved in DMSO.
Screening of a chemical library for synergy with aminocandin
A large-scale screen for antifungal synergy between a sub-inhibitory concentration of 
aminocandin and a collection of 38,758 chemicals obtained from Prestwick, ChemDiv and the  
French “Chimiothèque Nationale”24 was performed in 96-well plates using a Tecan Freedom 
EVO 200 platform. C. albicans wild-type cells of strain SC5314 were grown in the presence  
of 0.0156 mg/L aminocandin and 50 µM (on average) of each tested compound (dissolved in  
dimethyl sulfoxide, DMSO) in 100µl RPMI medium, starting from an OD600 of 0.01. Columns 
1 and 12 were used for controls: DMSO was used as a negative control to define growth of 
the cells without compound; 10 mg/L of aminocandin was used as a positive control to kill all  
cells. Cells were incubated for 24 h at 30°C and cell viability was measured using a resazurin  
assay25 through addition of resazurin-sodium salt to a final concentration of 100 mg/L. Plates 
were incubated for 2 h at room temperature (RT). While resazurin is naturally blue, its 
oxidation is associated with a change to red colour. To measure the colour change a dual 
wavelength measurement was performed (reference wavelength 604 nm, measurement  
wavelength 570 nm) using a Tecan Safire2 microplate reader. For each plate the Z´factor 26 was 
calculated and was above 0.55 (Supplemental Figure 1A). The data were normalized using the 
following formula: % viability = 100 x (sample value - average value of positive controls) /  
(average of negative controls - average of positive controls). Active compounds were defined 
as compounds causing <1% viability. Chemical families were defined using clustering 
methods based on similarity concept using the Tanimoto coefficient and the K-modes 
clustering algorithm27-29. The best compounds were ordered from the different libraries and 
validated using minimum inhibitory concentration (MIC) assays.
MIC and chequerboard microdilution assays
In order to define the antifungal activity of a compound, MIC assays were performed in RPMI 
1640 glutamax medium buffered with 50 mM Hepes. Compounds were diluted two fold in the  
concentration range 0.1 mg/L - 50  mg/L and 1.3x105 cells.mL-1 of the C. albicans wild-type 
strain SC5314 were added. The MIC assays were incubated for 24 h at 30°C and viability of  
the cells was measured using the resazurin assay as described above.
In order to assess the synergy between two compounds, checkerboad microdilution assays 
were performed in RPMI 1640 glutamax medium using 96-well plates. 30 The tested 
concentrations were 0.01-1 mg/L for aminocandin and caspofungin, 0.02-1.25 mg/L for 
fluconazole, 0.4-2.5 mg/L for amphotericin B, 0.008-0.5 mg/L for 5-fluorocytosine, 8-500 
mg/L for hygromycin B, 0.08-5 mg/L for nourseothricin and 0.4-25 mg/L for colistin. The 
starting inoculum was 2.5x103 cells/mL. Chequerboards were incubated for 24 h at 30°C and 
viability of the cells was measured using the resazurin assay as described above. The  
Fractional Inhibitory Concentration index (FICI) was calculated by using the formula: MIC of  
drug A tested in combination/MIC of drug A alone + MIC of drug B tested in 
combination/MIC of drug B alone and compounds were qualified as synergistic when the  
FICI was below or equal to 0.5.11
Fitness assay with barcoded S. cerevisiae knock-out collections
Fitness assays were performed with a homozygous and a heterozygous S. cerevisiae knock-
out collection: 4885 S. cerevisiae mutants from the systematic deletion collection of Giaever 
et al. (strain BY474131) were grown in individual wells in 96 deep-well plates at 30°C for 2 
days in YPD medium, pooled and aliquots were stored at -80°C. A diploid heterozygous 
mutant collection (Invitrogen 95401.H4Pool; Life Technologies, Saint Aubin, France) 
consisting of 5936 mutants was grown for 15 generations in YPD, pooled and aliquots were 
stored at -80°C. 
For each chemogenomics experiment, aliquots were thawed and cells were allowed to recover 
in YPD medium for 8 h at 30°C, under shaking. Pools of 3x106 cells of the homozygous 
mutants were transferred to 100 ml flasks in YPD and cells were grown for about 11  
generations at 30°C under the following conditions: With (1) no compound, (2) 0.00125 mg/L 
aminocandin, (3) 20 mg/L colistin and (4) the combination of 0.00125 mg/L aminocandin and 
5 mg/L colistin. The pool of heterozygous mutants was grown with (1) no compound, (2) 
0.002 mg/L aminocandin, (3) 30 mg/L colistin and (4) the combination of 0.002 mg/L  
aminocandin and 10 mg/L colistin.
Subsequently, 7x107 cells were recovered by centrifugation, washed once with cold sterile  
water and stored at -80°C until processing. The growth of individual strains in the different  
cultures was determined by amplifying, labeling and hybridizing the barcodes on custom  
barcode microarrays (Agilent G2509F - AMADID N°026035; Agilent, Massy, France). 
Briefly, genomic DNA from the collected cells was extracted with phenol-chloroform by  
extensive vortexing in the presence of glass beads (425-600 nm size). Primers U1 and KU 
(see Supplemental Table 1 for primer sequences) were used to amplify the upstream barcodes 
and primers KD and D1 to amplify the downstream barcodes. 25 cycles of PCR with an 
annealing temperature of 50°C were used. The resulting PCR products were verified by  
electrophoresis on an agarose gel and used in a labeling PCR reaction with the Cy3 or Cy5 5'-
labeled oligonucleotides U2comp for the upstream tags and D2comp for the downstream tags  
and unlabeled U1 and D1 as a control. Only 15 cycles of amplification were used in the  
labeling step. The labeled PCR products were mixed and precipitated in the presence of linear  
acrylamide and of a mixture of complementary oligonucleotides (U1, D1, U2block, D2block) 
in four fold molar excess to avoid binding of the fluorescently labeled oligonucleotides to the  
microarray probes. Hybridization was performed using the DIG Easy Hyb buffer (Roche 
Applied Science, Meylan, France), at 24°C, overnight, in a rotating Agilent hybridization 
chamber. The slides were washed in decreasing concentrations of SSPE buffer (10 mM 
potassium phosphate (pH 7.4), 150 mM NaCl, 0.5 mM EDTA, 0.05% (w/v) Triton X100) 
down to 0.2 x SSPE, dried and treated immediately with the Agilent Stabilization and Drying  
Solution to avoid ozone-induced degradation of the Cy5 fluorophore. Scanning was 
performed on a Genepix 4200AL scanner (Molecular Devices, Saint Grégoire, France) and 
the images were analysed using Axon Genepix Pro 7 (Molecular Devices). We filtered the  
data according to our previous estimates of the reliability of the microarray sig nal.32 Filtered 
data were normalized using the Loess algorithm (R package marray included in  
Bioconductor33) separately for signals coming from upstream or downstream barcodes. The 
average of the values for the upstream barcode and the downstream barcode was calculated. 
The log2 of the ratio between the signal obtained for a given mutant growing with and  
without drug was used as an estimate of the drug's effect on the growth rate of the mutant.
Confirmation of selected S. cerevisiae and C. albicans mutants
In order to confirm the data of the fitness screen we selected several strains of the  
homozygous and the heterozygous deletion mutant collections (Table 1) and retested them 
singularly. The respective strains were streaked on YPD plates and single colonies were used 
to isolate genomic DNA of the strains using the Epicentre MasterPure Yeast DNA purification 
kit (Tebu-bio, Le Perray en Yvelines, France). PCRs were performed using oligonucleotides  
binding to the up-stream region of the respective gene and on the KANMX4 cassette, which 
was used to delete the genes. Confirmed strains, i e those harbouring a correctly integrated 
marker cassette, were inoculated from an overnight culture to an OD600=0.002 in YPD 
medium and grown with (1) no compound, (2) 0.00125 mg/L aminocandin, (3) 20 mg/L 
colistin and (4) the combination of 0.00125 mg/L aminocandin and 5 mg/L colistin over night  
at 30°C (16 h). Subsequently, the OD600 of the strains was measured to determine the 
sensitivity of the respective strains. C. albicans mutant strains (Table 1) were tested using the 
same procedure except that cells were grown with (1) no compound, (2) 0.00125 mg/L 
aminocandin, (3) 30 mg/L colistin and (4) the combination of 0.00125 mg/L aminocandin and 
20 mg/L colistin.
Analysis of cell permeability using Propidium-Iodide staining
2x105 CFU/mL of the wild-type strain SC5314 were inoculated from an over-night culture in 
RPMI and grown for 1 h at 30°C. Subsequently, cells were grown in RPMI with (1) no 
compound, (2) 0.00125 mg/L aminocandin, (3) 20 mg/L colistin and (4) the combination of 
0.00125 mg/L aminocandin and 20 mg/L colistin. After 10, 30, 50 and 70 minutes growth at 
30°C, 4x106 cells were harvested, washed with 1x PBS, resuspended in 1x PBS and incubated 
for 3 min with 5µg Propidium Iodide (PI; Sigma-Aldrich) in the dark. Subsequently, the cells  
were washed with 1x PBS, resuspended in 1x PBS and analysed using a Miltenyi Biotec 
MACS QUANT FACS machine (Miltenyi, Paris, France). Cells treated with 70% ethanol for 
1 h were used as positive control while untreated cells were used as negative control. In order 
to analyse the data and to calculate the percentage of PI-stained cells, the software FlowJo  
version 7.6.5 (TreeStar Inc, Oregon, USA) was used. The raw data were analysed using the 
statistical test Chi2-Mantel-Haenszel.
Mouse model of systemic candidiasis
All animal experiments adhered to the EU Directive 86/609 on the approximation of laws,  
regulations and administrative provisions of Member States regarding the protection of 
animals used for experimental and other scientific purposes, and to related national 
regulations. All experiments were performed according to the guidelines of the European 
Convention For The Protection Of Vertebrate Animals Used For Experimental And Other  
Scientific Purposes (ETS No. 123). The protocol was approved by Institut Pasteur Health 
Center Animal Care Committee (Protocol number:10.455). Recovery of organs was 
performed following euthanasia of animals, and all efforts were made to minimize suffering.
In vivo interaction between colistin and caspofungin was evaluated using a mouse model of  
systemic infection. Ten weeks old BALB/c mice (Charles River, L’Arbresle, France) were  
immuno-supressed with 200mg/kg endoxan (cyclophosphamide; Baxter, Maurepas, France) 4 
days before infection and were infected intravenously with 104 colony forming units (CFUs) 
per mouse of C. albicans strain SC5314. Treatment with antifungals was performed 
intraperitoneally in a volume of 200 µl and started 24 hours after infection. For in vivo studies 
the less toxic prodrug colistin sodium methanesulfonate was used. Colistin sodium 
methanesulfonate (Sigma-Aldrich) was injected two times per day at a concentration of 40  
mg/kg34 while Cancidas™ (caspofungin; MSD) was used at a concentration of 0.3 mg/kg and 
injected once per day35. Mice were kept in groups of 10 for each treatment group. One group 
of mice was treated with colistin alone, one with caspofungin alone and one with caspofungin  
and colistin, at the given concentrations. The group of mice not treated received 200 µl of  
sterile saline i.p. At 3 days postinfection (p.i.), mice were euthanized by CO 2 asphyxiation. 
Kidneys of each animal were removed, weighed and homogenized in 1ml of sterile 0.15 M 
NaCl. Serial 10-fold dilutions of the homogenates were plated onto SD agar containing 50 
mg/L ticarcillin and 10 mg/L gentamycin and incubated for two days at 30°C. The fungal  
burden was determined by counting the CFUs and analysed using the software GraphPad 
Prism5. Data shown in Figure 6 represent pooled results of two independent experiments.
Results
Colistin is synergistic with echinocandins
In order to find compounds acting synergistically with the echinocandin aminocandin 12, a 
high-throughput screen was performed on a total of 38,758 molecules with a large diversity of  
chemical backbones. The compound collection comprised 16,224 commercial compounds  
[1,120 obtained from Prestwick Chemical (http://www.prestwickchemical.com/index.php?
pa=26) and 15,104 obtained from ChemDiv (http://chemistryondemand.com/compound-
library)] and 22,534 compounds from the French academic chemical library (Chimiothèque 
Nationale24, http://chimiotheque-nationale.enscm.fr/). Each compound at a final concentration  
around 50µM was combined with a sub-inhibitory dose of aminocandin (0.0156 mg/L) and 
growth of C. albicans SC5314 was recorded after 24h at 30°C using a resazurin assay for 
measuring cell viability. Data were normalized as percentage of viability relative to positive  
and negative controls. The Z’ factor26, which is a statistical test to define the quality of a large-
scale screen was above 0.55 for all plates, indicating the robustness and reliability of the assay  
(Supplemental Figure 1A). Five hundred and fifty five compounds were identified whose  
combination with aminocandin resulted in 100% growth inhibition (Supplemental Figure 1B) 
and were clustered into chemical families. A hundred and fifty six compounds selected within  
the different families were reevaluated using MIC tests and chequerboard assays. Among 
these, 98 showed antifungal activity independently of the addition of aminocandin while 58  
had no significant antifungal activity on their own but acted synergistically with aminocandin  
(data not shown). 
Colistin sulfate (referred to below as colistin) was chosen for further study since it exhibited  
the highest synergy with aminocandin in a chequerboard microdilution assay (FICI=0.14 in  
RPMI-Hepes, FICI=0.25 in RPMI-MOPS; Table 2). Colistin showed antifungal activity 
towards C. albicans strain SC5314 at concentrations equal or above 60 mg/L (data not 
shown). Colistin was also tested in combination with different classes of antifungals using  
chequerboard-assays and the FIC indices were calculated for each combination (Table 2). We 
found synergy with the other β-1,3-glucan synthase inhibitor caspofungin (FICI=0.26). With 
both caspofungin and aminocandin, synergy was observed from a concentration of 0.4 mg/L 
colistin and C. albicans growth was prevented at all echinocandin concentrations tested in 
combination with a concentration of 3.1 mg/L colistin and above (data not shown). Our data  
also indicated synergy of colistin with amphotericin B (FICI=0.27) and fluconazole 
(FICI=0.47), consistent with previously published data that showed synergy between these 
antifungals and polymyxin B.17,18 In contrast, colistin did not show synergism with 
nourseothricin and hygromycin B that act on protein synthesis (FICI=0.55 and data not 
shown) and 5-fluorocytosine that acts on DNA and RNA synthesis (FICI=1). 
We also tested whether colistin exhibited synergistic activity with aminocandin in other yeast  
species. We found synergism in all species tested with FICI ranging from 0.07 to 0.28 (Table  
2). Colistin also showed weak antifungal activity in C. lusitaniae, C. krusei, C. tropicalis and 
Y. lipolytica whereas MICs were equal or above 50 mg/L for the other species (Table 2). 
Taken together, these results showed that colistin, an antibiotic in clinical use, slightly  
increases the antifungal activity of amphotericin B and fluconazole, two drugs that target  
fungal membranes, and strongly potentiates the antifungal activity of cell wall β-1,3-glucan  
synthase inhibitors of the echinocandin family in yeasts.
Synergism of colistin and caspofungin in caspofungin- and fluconazole-resistant strains
The rising number of caspofungin- and fluconazole- resistant strains occurring in hospitals is  
of concern.5 Therefore, we tested whether colistin acted synergistically with caspofungin in C. 
albicans caspofungin- and fluconazole-resistant strains (Table 1). While caspofungin-resistant 
strains harboured mutations in the FKS1 gene that encodes β-1,3-glucan synthase targeted by 
echinocandins36, fluconazole-resistant strains had mutations in E R G 11 that encodes 
cytochrome P450 lanosterol 14-alpha-demethylase targeted by azoles37 and/or TAC1 that 
encodes a transcription factor regulating the expression of the drug efflux pump-encoding 
genes CDR1 and CDR2.38 Consistent with results obtained using C. albicans strain SC5314, 
we found that colistin acted synergistically with caspofungin or fluconazole in all C. albicans  
wild-type isolates tested (Table 2 and data not shown). Colistin acted synergistically with  
caspofungin in fluconazole-resistant strains but not in caspofungin-resistant strains (Table 2  
and data not shown). This suggested that efficacy of caspofungin towards its target was a 
prerequisite to observe synergy with colistin. Moreover, it indicated that colistin toxicity was 
not affected by increased expression of drug efflux proteins including Cdr1 and Cdr2.
Genome-wide fitness profiling of S. cerevisiae knock-out mutants reveals a role of 
sphingolipid and chitin biosynthesis in tolerance to the aminocandin/colistin 
combination
Collections of molecularly-barcoded heterozygous and homozygous knock-out S. cerevisiae  
mutants are available 31. Exposure of pools of both types of mutants to a given compound 
allows revealing those strains that show reduced or increased sensitivity to this compound.  
This strategy has been used successfully to obtain insights in the mode-of-action of  
antifungals 39. Hence, we screened a collection of 4885 barcoded S. cerevisiae haploid KO 
mutants (excluding genes essential for S. cerevisiae growth) and a collection of 5936 
barcoded S. cerevisiae heterozygous diploid KO mutants (including essential genes) for 
sensitivity to colistin, aminocandin, and the combination of aminocandin and colistin. Pools  
of deletion mutants were grown in YPD without compound, in the presence of 20 mg/L 
colistin (that led to a decrease in growth rate of about 10% allowing us to test the sensitivity  
of S. cerevisiae KO mutants to colistin alone), in the presence of 0.00125 mg/L aminocandin  
and in the presence of the combination of 0.00125 mg/L aminocandin and 5 mg/L colistin.  
Subsequently, cells treated with the different compounds or combination of compounds were  
compared to non-treated cells in order to identify those mutants that showed increased or  
decreased fitness in one of the three conditions tested (Supplemental Tables 2 and 3). Selected  
mutants identified in this manner were then tested individually in order to confirm the data of  
the high throughput experiments (Supplemental Figure 2).
Table 3 lists S. cerevisiae genes whose corresponding haploid gene deletion strains were most  
affected by treatment with colistin [log2(treated/untreated) < -0.7], aminocandin 
[log2(treated/untreated) < -0.7] or the combination of the drugs [log2(treated/untreated) < 
-1.0]. Enriched functional annotations for haploid mutants showing hypersensitivity to drugs 
were evaluated using the generic GO Term Finder (http://go.princeton.edu/cgi-
bin/GOTermFinder). “Glycosphingolipid biosynthetic process” was the only term 
significantly enriched (corrected p value 0.00119) among the 14 strains most affected by 
colistin treatment. The genes annotated to this term code for Sur1/Csg1 and Csg2, two  
proteins that act in a complex to catalyse the formation of mannose-inositol-P-ceramide, one 
of the sphingolipid components that concentrate with ergosterol in lipid rafts of the plasma 
membrane.40-42 Similarly, the term “Glycosphingolipid biosynthetic process” was enriched 
when functional annotations for the 20 heterozygous diploid mutants most sensitive to colistin 
were analysed (p=0.00598). Deletion of one copy of SUR1/CSG1 led to hypersensitivity of 
the heterozygous diploid strain to colistin as did the deletion of one copy of IPT1, coding for 
the enzyme that catalyses the next step in this pathway ie synthesis of mannose-(inositol-P)2-
ceramide from mannose-inositol-P-ceramide43, and the deletion of SUR4/ELO3 that encodes 
an elongase involved in sphingolipid biosynthesis44 (Supplemental Table 3). As shown in Fig. 
1 and Table 3, growth of haploid strains with deletions in sphingolipid biosynthesis genes was  
not altered in the presence of aminocandin. Therefore, the combination of colistin and  
aminocandin did not aggravate the fitness defect of these strains observed upon treatment with 
colistin alone even though “Glycosphingolipid biosynthetic process” was among the enriched  
GO terms (p=0.0085) found upon analysis of the 25 genes whose deletion conferred highest  
sensitivity to the aminocandin/colistin combination treatment.
We could not find any significant enrichment for a common annotation for the most affected  
haploid or heterozygous diploid strains from the screen using aminocandin alone. In contrast, 
two GO terms were highly enriched among the 25 haploid strains most sensitive to the  
combination of aminocandin and colistin: “fungal-type cell wall chitin biosynthetic process” 
(p=1.35x10-5, 4 genes - CHS3, CHS7, CHS6 and SKT5) and the broader category “cellular cell 
wall organization or biogenesis” (p=1.51x10-5, 9 genes, including chitin biosynthesis genes 
and SLT2, YPK1, FKS1, ROM2 and TUS1). As shown in Fig. 1, inactivation of these genes 
also resulted in increased sensitivity to aminocandin alone but to a lesser extent than the  
sensitivity observed upon treatment with the combination. The observation that chitin-
synthesis mutants with a decreased amount of chitin in their cell wall 45-49 have increased 
sensitivity to aminocandin is consistent with previously published data 39 and the role of chitin 
synthesis in protecting yeast cells against the cell wall alterations resulting from β-1,3-glucan 
synthase inhibition.50 However, the enhanced reduction in fitness observed with the  
combination of aminocandin and colistin suggested that combined defects in β-1,3-glucan and 
chitin synthesis might facilitate colistin antifungal activity. Intriguingly, strains deleted for the  
FKS1 and ROM2 genes, the former encoding one of the two catalytic subunits of the S.  
cerevisiae β-1,3-glucan synthase and the latter encoding a GDP/GTP exchange protein for the 
Rho1 regulatory subunit of β-1,3-glucan synthase51, were less affected than the average 
population of mutants by colistin treatment while they were hypersensitive to aminocandin 
and aminocandin/colistin combination treatments (Fig. 1).
Mutations in sphingolipid and chitin biosynthesis result in increased sensitivity to 
colistin in C. albicans
 Results presented above indicated that defects in sphingolipid biosynthesis increased  
sensitivity of S. cerevisiae to colistin and the colistin/aminocandin combination while defects 
in chitin biosynthesis increased sensitivity to this combination and aminocandin alone. In  
order to test whether this held true in C. albicans, we took advantage of existing C. albicans  
knock-out mutants in the MIT1, CSG2, IPT1, CHS3, CHS5 and CHS7 genes that encode 
orthologues of S. cerevisiae SUR1/CSG1, CSG2, IPT1, CHS3, CHS5, a n d CHS7.52-56 
Inactivation of MIT1 and CSG2 did not increase the sensitivity of C. albicans to colistin, 
aminocandin or their combination (data not shown). In contrast, inactivation of IPT1 resulted 
in enhanced sensitivity of C. albicans to colistin alone or in combination with aminocandin 
(Fig. 2A). Furthermore, this increased susceptibility was abolished upon reintroduction of a 
wild-type allele of IPT1 in the ipt1∆ mutant (Fig. 2A). Data presented in Fig. 2B showed that  
inactivation of CHS3 increased the sensitivity of C. albicans to the aminocandin/colistin 
combination while having no significant effect on the susceptibility to the individual drugs.  
Inactivation of CHS5 enhanced sensitivity of C. albicans to colistin alone or in combination 
with aminocandin while inactivation of CHS7 had no effect. Taken together, these results  
indicated that, as observed in S. cerevisiae, efficient sphingolipid and chitin biosynthesis 
protected C. albicans against the antifungal activity of colistin and the aminocandin/colistin  
combination, although the impact of inactivating orthologous genes in S. cerevisiae and C. 
albicans had somewhat different outcomes.
Colistin treatment increases membrane permeability of aminocandin-treated C. albicans  
cells
Colistin might achieve its antifungal activity through targeting of biological membranes, as  
described for its antibacterial activity.14 In order to test this hypothesis, we assessed the 
permeability of colistin- and/or aminocandin-treated C. albicans cells using the fluorescent 
dye propidium-iodide (PI) that enters cells only when the membrane has been  
permeabilized.57 C. albicans strain SC5314 cells were grown for 1 h at 30°C, treated for 
different durations with (1) no compound, (2) 0.00125 mg/L aminocandin, (3) 20 mg/L 
colistin and (4) the combination of 0.00125 mg/L aminocandin and 20 mg/L colistin, and the  
proportion of PI-stained cells was determined by flow cytometry. We found that a 
significantly larger amount of cells became stained with PI when treated with aminocandin  
and colistin relative to aminocandin alone (P <0.0001; Fig. 3). Untreated cells and cells  
treated with colistin alone were not stained by the dye. Therefore, these results indicated that  
colistin treatment increased the permeability of C. albicans cells provided that these had been 
exposed to aminocandin.
The colistin/caspofungin combination reduces fungal burden in kidneys of mice infected 
with C. albicans
We tested whether the synergistic effect of colistin with echinocandins in vitro could be 
recapitulated during systemic C. albicans infection in mice. We could not identify any 
condition where the combination between Cancidas™, the clinical formulation of  
caspofungin, and the less toxic prodrug colistin sodium methanesulfonate allowed improved  
survival of C. albicans-infected mice (data not shown). However, when we used a  
combination of 0.3 mg/kg Cancidas™ and 40 mg/kg colistin sodium methanesulfonate, we 
observed a slightly but significantly lower fungal burden in kidneys after 3 days of infection  
relative to the fungal burden in mice that had been treated with 0.3 mg/kg  caspofungin alone 
(Fig. 4; Mann Whitney test, p-value <0.05). Taken together, our results indicated that the  
combination between caspofungin and colistin might have the potential to decrease fungal  
burden during early stages of infection. 
Discussion
Colistin targets the fungal membrane
In this study, we have found that the antibiotic colistin has weak, if any, antifungal activity 
towards several hemiascomycetous yeasts but that this activity is highly enhanced through 
combination with echinocandins. Colistin is a member of the family of polymyxin antibiotics  
that target bacterial membranes and is currently used for the treatment of Pseudomonas 
aeruginosa and Acinetobacter baumannii infections as well as infections caused by multi-
resistant bacteria such as the recently emerged NDM-1 Escherichia coli a n d Klebsiella  
pneumoniae.58 Weak antifungal activity of colistin and polymyxin B towards several distantly 
related fungal species has already been reported15,16,18,34 and it has been proposed that they act 
at the fungal membrane. Indeed, colistin could trigger rapid efflux of ATP from germlings of 
Mucorales and alterations of membrane structure.34 Moreover, polymyxin B showed synergy 
with membrane-targeting antifungals such as azoles and polyenes17,18, an observation that we 
have extended to colistin in this study. Our results are consistent with this antifungal mode of  
action. Indeed, we could show that under conditions where the antifungal activity towards C. 
albicans could be manifested, e g in combination with the β-1,3-glucan synthase inhibitor 
aminocandin, C. albicans cells became significantly more permeable to the membrane 
impermeable fluorescent dye propidium-iodide57, than when treated with aminocandin alone. 
Furthermore, fitness profiling experiments performed using S. cerevisiae haploid and 
heterozygous diploid knock-out mutants showed that alteration of sphingolipid biosynthesis 
results in increased sensitivity to colistin.  Similarly, a C. albicans ipt1∆∆ mutant defective for 
one of the enzymes of sphingolipid biosynthesis showed increased sensitivity to colistin and 
the aminocandin/colistin combination. Sphingolipids are essential components of the 
eukaryotic plasma membrane, concentrating together with sterols at so-called lipid rafts where  
they play a variety of functions.42 Notably, S. cerevisiae csg1, csg2 and ipt1 and C. albicans  
ipt1 mutants that are impaired in the latest steps of mannose-inositol-phosphoceramide 
(MIPC) and mannose-(inositol phosphate)2-ceramide (M(IP)2C) biosynthesis show increased 
sensitivity to azoles and amphotericin B.39,53 Synergism of colistin with these antifungals and 
mutations that alter sphingolipid biosynthesis are therefore consistent with its targeting of  
fungal membranes and possibly lipid rafts within these membranes.
Synergy of colistin with echinocandins: a rationale?
We have shown that colistin is synergistic with echinocandins. Analysis of the topology of S.  
cerevisiae β-1,3-glucan synthase and the location of aminoacids whose changes render the 
enzyme resistant to echinocandins suggest that these drugs interact with regions of the β-1,3-
glucan synthase that are exposed to the external milieu or embedded in the outer leaflet of the  
plasma membrane.21 Therefore, synergy between colistin and echinocandins is unlikely to 
result from colistin-mediated increased influx of echinocandins into cells. Here, we would  
like to propose that echinocandin-mediated weakening of the cell wall facilitates colistin  
targeting of fungal membranes that might in turn reinforce the antifungal activity of  
echinocandins. As mentioned above, combination of aminocandin with colistin rendered C. 
albicans cells highly permeable to propidium iodide while colistin-treated cells appeared  
impermeable to this compound. This suggests that echinocandin treatment facilitated access  
of colistin to membranes and its membrane-targeted antifungal activity, similar to what has  
been shown for echinocandin-facilitated entry of antimicrobial peptides (AMP).59 
Consistently, synergy between colistin and echinocandins was lost in strains harbouring 
mutations in the FKS1 gene and rendering C. albicans resistant to echinocandins, suggesting 
that weakening of the cell wall through inhibition of β-glucan synthase was a 
prerequisite for colistin antifungal activity. Moreover, we have shown that sensitivity to  
aminocandin of S. cerevisiae and C. albicans mutants with defects in chitin synthesis was 
markedly aggravated when colistin was added. Chitin synthesis is triggered upon treatment of  
yeast cells by echinocandins and contributes to the tolerance to these drugs. 50,60,61 Our results 
are consistent with this observation and suggest that colistin might enhance the activity of  
aminocandin and the chitin biosynthesis requirement for survival of aminocandin-treated  
cells. While this might also be explained by the impact of impaired chitin biosynthesis on  
colistin access to the plasma membrane and its antifungal activity, it is probably not the case,  
as chitin-defective mutants did not show increased sensitivity to colistin alone. In contrast, S.  
cerevisiae mutants with defects in β-1,3-glucan synthesis showed intrinsically high tolerance 
to colistin that might reflect adaptative changes in the cell wall in response to constitutive  
lower β-1,3-glucan levels62, consequently reducing colistin ability to reach membranes. 
Mechanisms by which colistin could enhance the activity of echinocandins have not been  
investigated here. However, it can be proposed that colistin-induced perturbation of the 
plasma membrane might impair β-glucan synthase activity, rendering it more 
susceptible to echinocandins, or might facilitate membrane insertion of echinocandins. Yet, it  
should be noted that not all membrane-targeting drugs are synergistic with echinocandins. For 
instance, azoles and polyenes are not generally regarded as synergistic with echinocandins in  
Candida spp. although some examples of synergy have been reported.63-65 As mentioned 
above, synergy between cationic AMP and echinocandins has been observed.59,66 Polymyxins 
are cationic cyclic heptapeptides with a hydrophobic tail suggesting that they share properties 
with other AMP that could specifically impact fungal membranes and β-glucan 
synthase activity. Interestingly, we did not observe any synergy between colistin and several  
cell wall-targeting drugs (Congo red, calcofluor white, nykkomycin Z; data not shown) 
suggesting that there is specificity in the colistin/echinocandin synergy. 
Synergism of colistin and echinocandins in diverse fungal species and in a mouse model of  
systemic candidiasis 
In this study, we have observed in vitro synergy between colistin and echinocandins in several 
pathogenic yeasts, namely C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. 
krusei, as well as in fluconazole-resistant C. albicans strains. In contrast, no synergy could be 
observed between aminocandin and colistin in A. fumigatus (data not shown). Using a mouse 
model, we have shown that the colistin/caspofungin combination could possibly reduce fungal  
burden at early stages of systemic candidiasis relative caspofungin alone. However, this  
observation did not translate into an improvement of survival of animals suggesting that 
further demonstration of the efficacy of this drug combination in the treatment of systemic  
candidiasis will probably require optimizing delivery routes and evaluating pharmacodynamic  
interactions of caspofungin and colistin sodium methanesulfonate. Moreover, we believe that  
our results suggest that more emphasis should be put on the search and development of  
compounds that specifically target fungal membranes and could be synergistic with  
echinocandins.
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Legends to Figures
Figure 1: Colistin affects sphingholipid biosynthesis deficient strains and increases the 
sensitivity of chitin synthesis mutants to aminocandin. A pool of S. cerevisiae haploid 
deletion strains was treated with colistin (20 mg/L), aminocandin (0.00125 mg/L) or the 
combination of 0.00125 mg/L aminocandin and 5 mg/L colistin and grown for 11 generations  
in liquid medium. Relative growth rates, estimated using barcode-specific microarrays, were  
normalized and represented as log2 ratios of the signal obtained with treated versus untreated  
culture. Mutant strain behaviour in the different conditions is illustrated for genes that belong  
to functional categories that were found to be significantly enriched (sphingolipid  
biosynthesis, green; cell wall organization and biogenesis, blue and chitin synthesis, red, see  
text for details).
Figure 2: Efficient sphingolipid or chitin biosynthesis protects C. albicans cells of the 
combined antifungal activity of aminocandin and colistin. C. albicans strains with 
mutations in the IPT1 gene involved in sphingolipid biosynthesis (deltaIPT1, TPIPT1-4; 
deltaIPT1+IPT1, TPIPT1-4; Table 1) and in the CHS3, CHS5 and CHS7 genes involved in 
chitin biosynthesis (CACB3B-5, ∆CHS5_ARGplu, ∆CHS3_ARGplus, respectively; Table 1) 
and their parent strains (CAI4 and SN250_ARGplus; Table 1) were grown in the absence of 
drugs (untreated) or in the presence of aminocandin alone (AMC; 0.00125 mg/L), colistin  
alone (COL; 30 mg/L), and the combination of aminocandin (0.00125 mg/L) and colistin (20 
mg/L) (AMC + COL). Optical density was recorded after 16 h growth and is represented  
relative to the optical density obtained for the untreated wild-type cells. Data are mean of 2  
independent experiments, with bars indicating the range of values.
Figure 3: Colistin increases permeability of echinocandin-treated cells
Cells were left untreated or treated with colistin alone (COL, 20 mg/L), aminocandin alone  
(AMC, 0.00125 mg/L) or with the combination of both drugs (AMC + COL) and the 
proportion of propidium-iodide stained cells was measured by flow cytometry. The statistical  
test Chi2-Mantel-Haenszel was used to analyse the difference between cells treated with 
aminocandin alone and with the combination. At all time points the difference was significant  
(p < 0.0001).
Figure 4: The colistin/caspofungin combination reduces fungal burden in kidneys of C. 
albicans infected mice. Immuno-supressed female BALB/c mice were infected 
intravenously with 104 CFU/mouse of C. albicans strain SC5314. One group of mice was not 
treated, one was treated with colistin alone (40 mg/kg), one with caspofungin alone (0.3  
mg/kg) and one with caspofungin and colistin at the given concentrations. Mice were killed 
three days after infection and fungal burden in kidneys of mice was evaluated. * P<0.05. Note  
that only 7 mice untreated or treated with colistin alone were still alive on day 3 after  
infection, therefore the CFUs of only 7 kidneys are represented in the graph.
Supplemental Figure 1:
High-throughput screening for compounds acting synergistically with aminocandin. (A) 
Evaluation of the test using the calculated Z'-factor value plotted for each plate. (B)  
Distribution of the number of compounds as a function of the percentage of viability as 
defined in the material and methods section.
Supplemental Figure 2:
Confirmation of S. cerevisiae mutants exhibiting sensitivity towards the treatment in a 
fitness assay. Heterozygous- and homozygous mutants were grown for 16 h at 30°C without  
compound (-Amc -CS), in presence of aminocandin only (+Amc -CS), colistin alone (-Amc  
+CS) and the combination of both compounds (+Amc +CS).
Table 1: Yeast strains used in this study
Species Strain Type of strain Genotype Reference
C. albicans DPL1000 WT, parent of 20S, 22S and 36S D. Perlin
C. albicans 20S Caspofungin-resistant, Fks1S645F FKS1C1934T/FKS1C1934T 67
C. albicans 22S Caspofungin-resistant, Fks1S645Y FKS1C1934A/FKS1C1934A 67
C. albicans 36S Caspofungin-resistant,Fks1S645P FKS1T1933C/FKS1T1933C 67
C. albicans M70 WT, parent of C42
C. albicans C42 Caspfungin-resistant, Fks1F641S FKS1/FKS1





C. albicans DSY296 Fluconazole-resistant TAC1-5/TAC1-5 ERG11-5/ERG11-5 68
C. albicans DSY3987 Fluconazole-resistant ura3∆::FRT/ura3∆::FRT TAC1-5/TAC1-5 ERG11-
5/ERG11-5 RP10::CIp10
D. Sanglard
C. albicans DSY3988 Fluconazole-resistant ura3∆::FRT/ ura3∆::FRT tac1-5∆::hisG/tac1-5∆::hisG 
ERG11-5/ERG11-5 RP10::CIp10
D. Sanglard
C. albicans CAI4 ∆ura3::λimm434/∆ura3::λimm434 69
C. albicans TPIPT1-4 ∆ura3::λimm434/∆ura3::λimm434 
∆ipt1::hisG/∆ipt1::hisG
53
C. albicans TPIPT1-5 ∆ura3::λimm434/∆ura3::λimm434 
∆ipt1::hisG/∆ipt1::hisG::IPT1-URA3
53
C. albicans CACB3B-5 ∆ura3:: λimm434/1∆ura3:: λimm434 ∆chs3-
2::hisG/∆chs3-3::hisG_URA3_hisG_URA3_hisG
56
C. albicans SN152 arg4∆/arg4∆ leu2∆/leu2∆ his1∆/his1∆ 
URA3/ura3∆::λimm434 IRO1/iro1∆::λimm434
70




C. albicans ΔCHS5_ARGplus SN152 chs5∆::CmLEU2 /chs5∆::CdHIS1 
arg4Δ::CaARG4
54
C. albicans ΔCHS7_ARGplus SN152 chs7∆::CmLEU2 /chs7∆::CdHIS1 
arg4Δ::CaARG4
54
C. albicans ∆CSG2_ARGplus SN152 csg2∆::CmLEU2 /csg2∆::CdHIS1 
arg4Δ::CaARG4
54
C. albicans S11.A14 mit1-∆::hisG/mit1-∆::hisG-URA3-hisG 52
S. cerevisiae BY4741 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 23
S. cerevisiae BY4743 MATa his3∆1 leu2∆0 met15∆0 ura3∆0/ MATα  his3∆1 
leu2∆0 met15∆0 ura3∆0
23
S. cerevisiae sur∆ BY4741 sur1∆KanMX4 31
S. cerevisiae sur1∆ het BY4743 sur1∆KanMX4/SUR1 Invitrogen
S. cerevisiae csg2∆ BY4741 csg2∆KanMX4 31
S. cerevisiae gef1∆ BY4741 gef1∆KanMX4 31
S. cerevisiae erg6∆ BY4741 erg6∆KanMX4 31
S. cerevisiae vps74∆ BY4741 vps74∆KanMX4 31
S. cerevisiae trp1∆ BY4741 trp1∆KanMX4 31
S. cerevisiae chs3∆ BY4741 chs3∆KanMX4 31
S. cerevisiae chs5∆ BY4741 chs5∆KanMX4 31
S. cerevisiae chs6∆ BY4741 chs6∆KanMX4 31
S. cerevisiae chs7∆ BY4741 chs7∆KanMX4 31
S. cerevisiae skt5∆ BY4741 skt5∆KanMX4 31
S. cerevisiae ipt1∆het BY4743 ipt1∆KanMX4/IPT1 Invitrogen
S. cerevisiae sur4∆het BY4743 sur4∆KanMX4/SUR4 Invitrogen
Table 2: Synergistic activity of colistin with echinocandins in different yeast species
Strain (Phenotype) MIC of individual compound Optimal compound concentrations for 
observing synergy









Candida albicans SC5314 Aminocandin 0.5 60 0.06 0.39 0.14
Candida albicans SC5314 Caspofungin 0.5 60 0.125 0.39 0.26
Candida albicans SC5314 Fluconazole 0.31 60 0.08 12.5 0.47
Candida albicans SC5314 AmphotericinB 0.63 60 0.16 0.8 0.27
Candida albicans SC5314 Nourseothricin 2.5 60 1.25 3.1 0.55
Candida albicans SC5314 5-Fluorocytosine 0.25 60 0.25 0.39 1
Candida albicans DPL1000 (CasS FluS) Caspofungin 2.0 250 0.25 0.78 0.12
Candida albicans 36S (CasR FluS) Caspofungin 20 250 0.5 25 1.1
Candida albicans DSY294 (CasS FluS) Caspofungin 1.0 50 0.25 0.78 0.26
Candida albicans DSY3987 (CasS FluR) Caspofungin 0.63 125 0.16 0.39 0.26
Candida albicans DSY3988 (CasS FluR) Caspofungin 0.63 125 0.16 0.39 0.26
Candida glabrata NEM_7118432 Aminocandin 0.5 50 0.06 0.39 0.14
Candida lusitaniae NEM_7104301 Aminocandin 1.0 25 0.03 0.39 0.07
Candida krusei ATCC6258 Aminocandin 5.0 25 0.06 0.78 0.09
Candida tropicalis NEM_7114236 Aminocandin 2.5 12.5 0.63 0.39 0.14
Candida parapsilosis NEM_7103546 Aminocandin 5.0 100 0.08 1.56 0.15
Yarrowia lipolytica NEM_7115511 Aminocandin 12.5 12.5 1.25 1.56 0.25
Saccharomyces cerevisiae BY4741 Aminocandin 0.13 25 0.13 0.39 0.28
1 Fractional Inhibitory Concentration index
Table 3: Saccharomyces cerevisiae haploid gene deletion strains most affected by treatment with colistin, aminocandin or combination of 
the drugs. Selection was done using a threshold value of -0.7 for single drug treatment and -1.0 for the combination.
ORF Name Colistin1 Aminocandin1 Combined1 Description2
Glucan synthesis
YKL126W YPK1 -1.3 -1.0 -1.3 Protein kinase that affects FKS1 - sphingolipid mediated cell integrity 
signalling 
YLR425W TUS1 0.1 -0.3 -1.7 GEF that modulates Rho1 GTPase
YLR371W ROM2 1.1 -0.3 -1.6 GDP/GTP exchange protein (GEP) for Rho1p and Rho2p




-0.1 -0.6 -1.4 Overlaps MRM1 - chitin synthesis
YBR023C CHS3 0.1 -0.6 -2.2 Chitin synthase
YBL061C SKT5 0.2 -0.6 -2.6 Activator ot Chs3 - chitin biosynthesis
YHR142W CHS7 0.3 -0.4 -2.1 Unknown function, chitin biosynthesis
YJL099W CHS6 0.3 -0.3 -1.4 Mediates export or cargo proteins, including Chs3, from Golgi to plasma 
membrane
PKC pathway
YJL095W BCK1 -0.1 -0.4 -2.5 MAP kinase kinase kinase in the PKC pathway
YHR030C SLT2 0.1 -0.3 -1.9 MAP kinase in the PKC pathway
Sphingolipid synthesis
YBR036C CSG2 -1.4 0.0 -1.2 ER membrane protein required for mannosylation of 
inositolphosphorylceramide
YPL057C SUR1 -1.2 0.0 -1.0 Mannosylinositol phosphorylceramide (MIPC) synthase in complex with Csg2
YLR372W SUR4 -0.6 -0.4 -1.1 Fatty acid and sphingolipid biosynthesis
Golgi function
YER151C UBP3 -1.1 -0.4 -0.9 Ubiquitin-specific protease that acts in complex with Bre5 to co-regulate 
transport between the ER and Golgi
YKR001C VPS1 -0.9 0.0 -0.5 Dynamin-like GTPase required for vacuolar sorting
YDR372C VPS74 -0.8 0.0 -0.7 Protein required for Golgi localization of glycosyltransferases
YFL025C BST1 -0.8 -0.5 -1.4 GPI inositol deacylase in the ER
YAL026C DRS2 -0.6 0.0 -1.3 Aminophospholipid translocase (flippase)
YJL183W MNN11 -0.2 -0.6 -1.9 Golgi mannosyltransferase complex component
YOR327C SNC2 0.6 -0.8 0.0 Vesicle membrane receptor protein (v-SNARE)
Aromatic aminoacid metabolism
YBR069C TAT1 -1.2 -0.2 -1.0 Aminoacid transporter
YER090W TRP2 -0.8 -0.1 -0.5 Anthranilate synthase - tryptophan biosynthesis
YGL148W ARO2 -0.8 -0.2 -0.7 Chorismate synthase - aromatic acid biosynthesis
Other roles
YOR200W MRM1* -1.0 -1.2 -0.6 Overlaps MRM1 - mitochondrial enzyme
YIR023W DAL81 -0.8 0.8 0.0 Positive regulator of genes in multiple nitrogen degradation pathways
YKL048C ELM1 -0.8 -0.3 -0.6 Protein kinase involved in cellular morphogenesis
YCR044C PER1 -0.5 -0.1 -1.4 ER protein required for GPI-phospholipase A2 activity
YOR080W DIA2 -0.3 -1.0 0.0 Origin-binding F-box protein that forms an SCF ubiquitin ligase complex with 
Skp1p and Cdc53
YDR146C SWI5 -0.2 -0.6 -1.5 Transcription factor
YER111C SWI4 -0.1 0.0 -1.8 Transcription factor
YPL066W 0.0 -0.7 -1.8 Unknown function
YPL086C ELP3 0.1 -0.7 -0.4 Subunit of Elongator complex - modifies tRNAs
YPL158C AIM44 0.1 -0.6 -1.4 Unknown function
YGR228W 0.2 -0.2 -1.1 Overlaps SMI1 - involved in the regulation of cell wall synthesis
YFL001W DEG1 0.3 -0.8 0.1 tRNA:pseudouridine synthase
YLR140W RRN5* 0.3 -1.2 0.0 Overlaps RRN5 - involved in pol I transcription of rDNA
YBR200W BEM1 0.7 -0.2 -1.7 Involved in establishing cell polarity and morphogenesis
1 Numbers represent log2 of the ratio treated over control for each strain







Supplemental Table 1: Oligonucleotides used in this study
Name Application Sequence
U1 Amplification of up-stream barcode GAT GTC CAC GAG GTC TCT
KU Amplification of up-stream barcode; confirmation of mutants AAG AAG AAC CTC AGT GGC
KD Amplification of down-stream barcode GGA TCT TGC CAT CCT ATG
D1 Amplification of down-stream barcode CGG TGT CGG TCT CGT AG
U2comp Labelling of up-stream barcode GTC GAC CTG CAG CGT ACG
D2comp Labelling of down-stream barcode CGA GCT CGA ATT CAT CGA T
U2block Block fluorescently labelled primers CGT ACG CTG CAG GTC GAC
D2block Block fluorescently labelled primers ATC GAT GAA TTC GAG CTC G
ScSUR1-up confirm homozygous and heterozygous S. cerevisiae sur1∆ strain CGG AAG ACA CTT TTC ATT TTC
ScCSG2-up confirm S. cerevisiae csg2∆ strain GGA GGC TAT GTG AAC GTG
ScGEF1-up confirm S. cerevisiae gef1∆ strain CAC CGC CTG TTC TCC AGT
ScERG6-up confirm S. cerevisiae erg6∆ strain CCC TTA TCT GTT TTA CTT TCG
ScVPS74-up confirm S. cerevisiae vps74∆ strain GCA GTT TCA TTG TTG GCT ATA
ScTRP1-up confirm S. cerevisiae trp1∆ strain GGG AGG GCA TTG GTG ACT
ScCHS3-up confirm S. cerevisiae chs3∆ strain CCG ATT TGC AAA GTT CTC GA
ScCHS5-up confirm S. cerevisiae chs5∆ strain GCG TAG ATG CTA AAT GTT ATC
ScCHS6-up confirm S. cerevisiae chs6∆ strain GGA ATA GAG GAT CTT AAC AAA
ScCHS7-up confirm S. cerevisiae chs7∆ strain GCT GTC TCC ACG TGG AAA
ScSKT5-up confirm S. cerevisiae skt5∆ strain GTG TTG GCA CTT GAC TTT AG
ScIPT1-up confirm heterozygous S. cerevisiae ipt1∆ strain CCA CCC TAA CTG TTC CTT T
ScSUR4-up confirm heterozygous S. cerevisiae sur4∆ strain GAC AGC TCT TCA CTC GCT T
